Anti-high mobility group box-1 antibody therapy for traumatic brain injury

Y Okuma, M Nishibori - … : Journal of the Pharmaceutical Society of …, 2014 - europepmc.org
Y Okuma, M Nishibori
Yakugaku zasshi: Journal of the Pharmaceutical Society of Japan, 2014europepmc.org
Traumatic brain injury (TBI) is one of the major causes of death and aftereffects in young
individuals worldwide; however, efficient therapies for TBI are lacking at present. High
mobility group box-1 (HMGB-1), which is recognized as a representative of danger-
associated molecular patterns (DAMPs), plays an important role in triggering inflammatory
responses in many types of diseases. We presented the involvement of HMGB-1 in TBI and
evaluated the ability of intravenously administered neutralizing anti-HMGB-1 monoclonal …
Traumatic brain injury (TBI) is one of the major causes of death and aftereffects in young individuals worldwide; however, efficient therapies for TBI are lacking at present. High mobility group box-1 (HMGB-1), which is recognized as a representative of danger-associated molecular patterns (DAMPs), plays an important role in triggering inflammatory responses in many types of diseases. We presented the involvement of HMGB-1 in TBI and evaluated the ability of intravenously administered neutralizing anti-HMGB-1 monoclonal antibody (mAb) to attenuate brain injury. Anti-HMGB-1 mAb may provide a novel and effective therapy for TBI by protecting against blood brain barrier disruption and reducing the inflammatory responses induced by HMGB-1.
europepmc.org